Cargando…
An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833537/ http://dx.doi.org/10.1186/ar1407 |
| _version_ | 1782178409794764800 |
|---|---|
| author | Eisenberg, RA Khan, S Stansberry, J Tsai, D Kolasinski, S Rieder, E Kotzin, B Looney, RJ Strieber, C Albert, D |
| author_facet | Eisenberg, RA Khan, S Stansberry, J Tsai, D Kolasinski, S Rieder, E Kotzin, B Looney, RJ Strieber, C Albert, D |
| author_sort | Eisenberg, RA |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2833537 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2004 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-28335372010-03-08 An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus Eisenberg, RA Khan, S Stansberry, J Tsai, D Kolasinski, S Rieder, E Kotzin, B Looney, RJ Strieber, C Albert, D Arthritis Res Ther Poster Presentation BioMed Central 2004 2004-09-13 /pmc/articles/PMC2833537/ http://dx.doi.org/10.1186/ar1407 Text en |
| spellingShingle | Poster Presentation Eisenberg, RA Khan, S Stansberry, J Tsai, D Kolasinski, S Rieder, E Kotzin, B Looney, RJ Strieber, C Albert, D An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus |
| title | An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus |
| title_full | An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus |
| title_fullStr | An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus |
| title_full_unstemmed | An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus |
| title_short | An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus |
| title_sort | open-label safety and efficacy study of an anti-cd20 antibody (rituximab, rituxan) for anti-b-cell therapy in the treatment of systemic lupus erythematosus |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833537/ http://dx.doi.org/10.1186/ar1407 |
| work_keys_str_mv | AT eisenbergra anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT khans anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT stansberryj anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT tsaid anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT kolasinskis anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT riedere anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT kotzinb anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT looneyrj anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT strieberc anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT albertd anopenlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT eisenbergra openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT khans openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT stansberryj openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT tsaid openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT kolasinskis openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT riedere openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT kotzinb openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT looneyrj openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT strieberc openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus AT albertd openlabelsafetyandefficacystudyofananticd20antibodyrituximabrituxanforantibcelltherapyinthetreatmentofsystemiclupuserythematosus |